BioCentury | Nov 9, 2015
Clinical News

CHAM: Phase III started

...Osiris began a single-blind, placebo-controlled, U.S. Phase III trial to compare OTI-15-01 plus standard of care...
...Product: CHAM ( OTI-15-01 ) Business: Dermatology Molecular target: NA Description: Cryopreserved human amniotic membrane (CHAM...
BioCentury | Mar 10, 2003
Company News

Lipid Sciences board of directors update

Lipid Sciences Inc. (LIPD), Pleasanton, Calif. Business: Cardiovascular, Infectious diseases Resigned: Bill Cham WIR Staff...
BioCentury | Dec 13, 1999
Finance

The living dead

...Healthcare Division is underpinned by 24 sales reps selling gastroenterological products licensed from Falk AG (Cham...
BioCentury | Dec 23, 1996
Company News

Chrysalis International, DNX Corp., BioClin Group deal

...share). Chrysalis International Corp. (CRLS), Raritan, N.J. DNX Corp. (DNXX), Raritan, N.J. BioClin Group , Cham...
BioCentury | Aug 26, 1996
Company News

DNX Corp., BioClin International deal

...be treated as a pooling of interests. DNX Corp. (DNXX), Raritan, N.J. BioClin International , Cham...
Items per page:
1 - 5 of 5